Co-Diagnostics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Legal Proceedings
Item 1. Legal Proceedings
Stadium Capital Securities Class Action (Southern District of New York)
On July 28, 2026, the parties entered into a binding term sheet setting forth the material terms of a proposed settlement of the Stadium Capital securities class action. On August 14, 2026, the parties executed a definitive Stipulation and Agreement of Settlement (the “Settlement Agreement”), pursuant to which the defendants agreed to pay, or cause to be paid, an aggregate of $6.5 million into a settlement fund in exchange for the settlement and release of claims asserted in the action. The proposed settlement does not constitute an admission of wrongdoing or liability by the Company or the other defendants.
On August 17, 2026, the United States District Court for the Southern District of New York entered an order preliminarily approving the proposed settlement and directing that notice be provided to members of the settlement class. The Court has scheduled a settlement fairness hearing for December 8, 2026, at which it will consider whether to grant final approval of the settlement. The settlement remains subject to final court approval, satisfaction of applicable conditions and entry of a final judgment dismissing the action with prejudice. There can be no assurance that the settlement will receive final approval or become effective.
Co-Diagnostics, Inc. v. Hukui Technology, Inc., et al. Third Judicial District Court, Salt Lake County, Utah
As previously disclosed, on March 25, 2026, the trial court issued Findings of Fact, Conclusions of Law, and a ruling in favor of the Company on its declaratory judgment claim and on all remaining counterclaims asserted by Hukui Technology, Inc., Hukui Tech, Inc. and Hukui Bio Co., Ltd. The court concluded, among other things, that the Company did not breach any agreement with the defendants and that the defendants were not entitled to damages. Final judgment was entered on April 10, 2026 and was amended on April 27, 2026 to include costs.
On May 11, 2026, the defendants filed a notice of appeal seeking review of the final judgment in its entirety. On June 2, 2026, the Utah Supreme Court transferred the appeal to the Utah Court of Appeals for disposition pursuant to Rule 42(a) of the Utah Rules of Appellate Procedure. The defendants have since filed their opening brief in support of the appeal. The appeal remains pending. The Company believes the trial court’s judgment was correct and intends to defend the judgment vigorously, but there can be no assurance as to the outcome of the appeal.
Robert Salna v. Co-Diagnostics, Inc., et al. Third Judicial District Court, Salt Lake County, Utah
As previously disclosed, in February 2024, Robert Salna filed an action against the Company and certain current or former officers arising from a 2018 loan transaction and the alleged failure to issue warrants or other equity-based compensation in connection with that transaction. The original complaint asserted claims including breach of contract, breach of fiduciary duty, fraud, negligent misrepresentation, and violations of federal and Utah securities laws. The plaintiff seeks compensatory and other damages.
On May 26, 2026, the court granted the Company’s motion to dismiss. The court dismissed with prejudice the breach-of-contract claim against the individual defendants. The court dismissed without prejudice the breach-of-contract claim against the Company and the claims for breach of fiduciary duty, fraud, negligent misrepresentation, and violations of the Utah Securities Act. The court also determined that it lacked subject-matter jurisdiction over the plaintiff’s claim under the Securities Act of 1933 and dismissed that claim without prejudice. The court permitted the plaintiff to seek leave to amend the complaint.
On July 9, 2026, the plaintiff filed a motion for leave to file a proposed first amended complaint. The proposed amended complaint would remove two individual defendants and the federal securities claim and would assert claims against the Company, Dwight H. Egan, and Reed L. Benson for breach of contract, fraud or intentional misrepresentation, negligent misrepresentation, breach of fiduciary duty or an alleged transaction-specific duty, violation of the Utah Uniform Securities Act, and declaratory relief. The proposed amended complaint continues to allege that the plaintiff was promised warrants in connection with the $2.0 million loan transaction and seeks damages and other relief based on the alleged failure to issue those warrants.
The defendants have opposed the motion for leave to amend, arguing that the proposed amendment is unjustifiably delayed and that the proposed claims remain legally deficient and would be futile. The motion remains pending. The Company believes the plaintiff’s claims are without merit and intends to continue defending the action vigorously, but there can be no assurance as to the outcome.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.